ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
COMPANY: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 11
Strengths 11
Strong sales and high forecast operating profits to 2011 11
Weaknesses 11
Exposure to generic competition, significantly hampering growth prospects 11
Opportunities 12
Use search & development business model to bolster pipeline and offset declines from currently marketed portfolio 12
Threats 12
Failure of pipeline products to reach the market 12
Table of Contents 13
Table of figures 15
Chapter 3 Quarterly update 16
Latest quarterly sales 16
Latest prescription pharma product news 16
Q1 2010 16
Q4 2009 16
Q3 2009 17
Q2 2009 17
Q1 2009 17
Latest corporate news 18
Q1 2010 18
Q4 2009 18
Q3 2009 18
Q2 2009 18
Q1 2009 19
Future product milestones 19
Chapter 4 Company introduction 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 21
Current corporate structure 21
Forest Pharmaceuticals 21
Inwood Laboratories 21
Chapter 5 Company sales 23
Key findings 23
Prescription pharmaceutical sales and growth rate analysis, 2002-14 24
Product analysis 25
Product analysis, 2002-08 26
Product analysis, 2008-14 28
Therapy area analysis 30
Geographic analysis 32
Launch/core/expiry analysis 34
Explanation of launch/core/expiry analysis 34
Launch analysis, 2008-14 35
Core analysis, 2008-14 36
Expiry analysis, 2008-14 36
Generics analysis, 2008-14 37
Launch/core/expiry configuration, 2008-14 38
Molecule type analysis 39
Externalization analysis 41
Chapter 6 Company financials 43
Key findings 43
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 44
Operating costs and profit analysis 45
Operating costs and profit analysis, 2002-08 46
Operating cost ratio and profit margin analysis, 2002-08 47
Operating cost ratio and profit margin analysis, 2008-14 47
Operating costs and profit analysis, 2008-14 48
Chapter 7 Key products and competitors 50
Overview 50
CNS 51
Lexapro 51
Overview 51
Sales forecast 52
Namenda 53
Overview 53
Sales forecast 54
Savella 55
Overview 55
Sales forecast 56
Chapter 8 Appendix 58
References 58
Abbreviations 58
Exchange rates 59
About Datamonitor 60
About Datamonitor Healthcare 60
Datamonitor consulting 60
Disclaimer 62
List of Tables
Table 1: Forest - PharmaVitae forecasts at a glance 8
Table 2: Forest quarterly sales ($m), Q308-Q309 16
Table 3: Forest future product milestones, 2010-12 19
Table 4: Forest product portfolio overview ($m), 2002-08 26
Table 5: Forest product portfolio overview ($m), 2008-14 28
Table 6: Forest prescription pharmaceutical sales by therapy area ($m), 2008-14 31
Table 7: Forest prescription pharmaceutical sales by geographic region ($m), 2008-14 33
Table 8: Forest launch portfolio overview ($m), 2008-14 35
Table 9: Forest core portfolio overview ($m), 2008-14 36
Table 10: Forest expiry portfolio overview ($m), 2008-14 36
Table 11: Forest generics portfolio overview ($m), 2008-14 37
Table 12: Forest prescription pharmaceutical sales by molecule type ($m), 2008-14 40
Table 13: Forest prescription pharmaceutical sales by source ($m), 2008-14 42
Table 14: Total Forest sales by business unit ($m), 2002-08 44
Table 15: Forest operating revenue/cost analysis ($m), 2002-08 46
Table 16: Forest operating cost ratio analysis (% of total revenues), 2002-08 47
Table 17: Forest operating cost ratio analysis (% of total revenues), 2008-14 47
Table 18: Forest operating revenue/cost analysis ($m), 2008-14 48
Table 19: Key products overview 50
Table 20: Lexapro: overview 51
Table 21: Lexapro: sales forecast ($m), 2008-14 52
Table 22: Namenda: overview 53
Table 23: Namenda: sales forecast ($m), 2008-14 54
Table 24: Savella: overview 55
Table 25: Savella: sales forecast ($m), 2008-14 56
Table 26: Exchange rates, 2009 59
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Forest prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Forest's financial performance ($m), 2002-14 7
Figure 4: Forest's gap to 2008-14 positive sales growth 9
Figure 5: Forest SWOT analysis 11
Figure 6: Current corporate structure 22
Figure 7: Forest prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 24
Figure 8: Key product sales ($m), 2002-14 25
Figure 9: Forest key sales growth drivers and resistors ($m), 2002-08 27
Figure 10: Forest key sales growth drivers and resistors ($m), 2008-14 29
Figure 11: Forest prescription pharmaceutical sales by therapy area ($m), 2002-14 30
Figure 12: Forest prescription pharmaceutical sales by geographic region ($m), 2002-14 32
Figure 13: Forest launch/core/expiry configuration ($m), 2008-14 38
Figure 14: Forest prescription pharmaceutical sales by molecule type ($m), 2002-14 39
Figure 15: Forest prescription pharmaceutical sales by source ($m), 2002-14 41
Figure 16: Forest operating revenue/cost analysis ($m), 2002-14 45
[Inhaltsverzeichnis ausblenden]
